Pharmaceutical Industry · global
Questions Over Middlemen for Lifesaving Drugs: Whistleblowers Challenge Multinational Drugmakers’ Sales Bonuses in Russia
A cross-border investigation shifts the focus of Russia’s procurement of high-priced drugs to bonuses paid by drugmakers to distributors. Procurement records show limited competition, but direct payment evidence establishing whether the bonuses reached officials remains lacking.
The commercial arrangements through which lifesaving drugs travel from manufacturers to hospitals may also affect how many people healthcare budgets can serve. The International Consortium of Investigative Journalists (ICIJ), Russian investigative outlet Proekt and Swiss outlet Republik published a joint investigation on November 2, revealing arrangements under which multinational drugmakers paid substantial sales bonuses to distributors in Russia, along with suspicions that these arrangements involved improper influence over public procurement.
The investigation concerns four whistleblower submissions filed with the U.S. Securities and Exchange Commission (SEC) between July 2024 and July 2025, targeting MSD, Eli Lilly, AstraZeneca and Novartis, respectively. The submissions allege that some distributors used the profit margins provided by drugmakers to channel benefits to healthcare officials and hospital administrators to secure orders. These are whistleblower allegations, not violations established by regulators.
Procurement records provide some verifiable leads. ICIJ’s analysis found that R-Pharm secured approximately $360 million in public procurement contracts for Keytruda between 2020 and 2022; during the same period, approximately 96% of tenders for the cancer drug attracted only one bidder. However, a single bid alone is insufficient to prove bribery. R-Pharm said it was MSD’s authorized local manufacturing partner and denied making improper payments to obtain contracts.
Republik reported that, according to the whistleblower submissions, some Novartis distributor bonuses reached 25% to 30% of the order value. The investigation also extended to treatments for rare diseases: all six public tenders for the gene therapy Zolgensma held since 2022 were awarded to the Pharmimex group, totaling $277 million. These records show a concentration of supply, but cannot directly establish whether improper benefits were transferred.
Roche was not a subject of the four SEC whistleblower submissions, but Republik separately examined its Russian cancer drug sales using material from the same source. The report said Roche’s breast cancer drugs Perjeta and Kadcyla were supplied in part through R-Pharm. Roche did not provide specific details about its partner arrangements, emphasizing in its response that it continued to provide Russian patients with access to lifesaving and essential medicines.
Responding to the allegations, Novartis said it had completed an in-depth investigation but did not disclose the findings; AstraZeneca declined to comment, while MSD and Eli Lilly did not respond to ICIJ’s requests for comment. ICIJ also noted that sales bonuses are a common commercial practice in the pharmaceutical industry and that the whistleblower submissions provided no evidence of direct payments from distributors to officials. Republik likewise cautioned that the documents did not establish the amounts of individual suspected bribes.
This leaves two questions that must be answered separately: whether procurement was sufficiently competitive, and where distributor profits ultimately went. Public records are available to examine the former, while the latter still requires more complete financial records and investigative findings. For patients who rely on public healthcare to access high-priced therapies, clarifying this part of the supply chain bears on whether limited budgets can truly translate into opportunities for treatment.